序贯膀胱内灌注吉西他滨和多西他赛治疗未接受卡介苗的高危非肌层浸润性膀胱癌
本研究回顾性分析了2013年5月至2021年4月在本机构接受吉西他滨联合多西他赛(Gem/Doce)序贯膀胱内灌注治疗的107例未接受卡介苗(BCG)的高危非肌层浸润性膀胱癌(NMIBC)患者。中位随访15个月,6、12、24个月无复发生存率分别为89%、85%、82%,无患者出现疾病进展或死于膀胱癌,24个月总生存率84%。作者认为Gem/Doce对未接受BCG的NMIBC有效且耐受良好,需进一步研究。
要点
- 未接受BCG的高危NMIBC患者接受Gem/Doce灌注后,24个月无复发生存率为82%。
- 研究中无患者出现疾病进展或死于膀胱癌,24个月总生存率为84%。
- 共发生92例不良事件,仅1例≥3级,4%患者未能完成完整诱导疗程。
核心结论
- Gem/Doce是未接受BCG的NMIBC有效且耐受良好的疗法,需进一步研究。
研究设计与样本
- 回顾性研究,纳入2013年5月至2021年4月在本机构接受Gem/Doce治疗的107例未接受BCG的高危NMIBC患者。
主要发现
- 中位随访15个月,6、12、24个月无复发生存率分别为89%、85%、82%。
- 有无原位癌患者复发率相似(p=0.42)。
- 无患者出现疾病进展或死于膀胱癌,1例因终末期下尿路症状行膀胱切除术。
- 24个月总生存率为84%。
- 共发生92例不良事件,其中1例≥3级,4例(4%)患者未能接受完整诱导疗程。
关键数值与推荐
- 患者接受6周每周1次序贯膀胱内灌注吉西他滨1 g和多西他赛37.5 mg,完全经尿道膀胱肿瘤切除术后开始。
- 首次随访无病生存者开始每月维持治疗,持续2年。
临床怎么用
- 本研究中心的做法是在BCG短缺时,对未接受BCG的高危NMIBC患者使用Gem/Doce。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bacillus Calmette-Guérin (BCG) is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive bladder cancer (NMIBC). In response to the BCG shortage, gemcitabine plus docetaxel (Gem/Doce) has been utilized at our institution in the BCG-naïve setting. We report the outcomes of patients with high-risk BCG-naïve NMIBC treated with Gem/Doce. MATERIALS AND METHODS: We retrospectively reviewed patients with BCG-naïve high-risk NMIBC treated with Gem/Doce from May 2013 through April 2021. Patients received 6 weekly intravesical instillations of sequential 1 gm gemcitabine and 37.5 mg docetaxel after complete transurethral resection of bladder tumor. Monthly maintenance of 2 years was initiated if disease-free at first followup. The primary outcome was recurrence-free survival. Survival was assessed with the Kaplan-Meier method, indexed from the first Gem/Doce instillation. Adverse events were reported using CTCAE (Common Terminology Criteria for Adverse Events) v5 (National Cancer Institute, Bethesda, Maryland). Differences were assessed with the log-rank test. RESULTS: There were 107 patients with a median followup of 15 months included in the analysis. Patients had high-risk characteristics including 47 with any carcinoma in situ and 55 with T1 disease. Recurrence-free survival was 89%, 85% and 82% at 6, 12 and 24 months, respectively. Recurrence rates were similar between patients with or without carcinoma in situ (p=0.42). No patient had disease progression or died of bladder cancer. One patient underwent cystectomy due to end-stage lower urinary tract symptoms. Overall survival was 84% at 24 months. There were 92 adverse events (1 ≥grade 3), and 4 (4%) patients were unable to receive a full induction course. CONCLUSIONS: Gem/Doce is an effective and well-tolerated therapy for BCG-naïve NMIBC. Further investigation is warranted.
引用
- McElree IM, Steinberg RL, Martin AC, et al. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer. J Urol. 2022. PMID: 35892270. doi:10.1097/JU.0000000000002740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。